Provided by Tiger Trade Technology Pte. Ltd.

SCYNEXIS Inc

5.10
-0.1200-2.30%
Post-market: 5.100.00000.00%19:30 EDT
Volume:35.18K
Turnover:183.62K
Market Cap:50.64M
PE:-3.82
High:5.41
Open:5.29
Low:5.05
Close:5.22
52wk High:10.48
52wk Low:3.53
Shares:9.93M
Float Shares:7.36M
Volume Ratio:0.51
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3352
EPS(LYR):-1.3793
ROE:-18.38%
ROA:-20.82%
PB:0.76
PE(LYR):-3.70

Loading ...

Scynexis is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 13

Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change

Reuters
·
Aug 12

Scynexis Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Codexis Q2 Net Loss Narrows, Helped by Lower Operating Expenses

Reuters
·
Aug 12

Achieve Life Sciences Q2 Loss Widens on Warrant Liabilities

Reuters
·
Aug 11

SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate

Benzinga Earnings
·
Aug 11

Scynexis Q2 Swings to Profit on Warrant Adjustment; Advances Drug Studies

Reuters
·
Aug 11

Scynexis - May Receive up to $146 Mln in Annual Net Sales Milestones & Net Royalties in the Low to Mid-Single Digit Range

THOMSON REUTERS
·
Aug 11

Scynexis Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 11

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Scynexis Q2 Net Income Swings to USD 7.4 Million; Revenue Drops 82.8% to USD 235,000

Reuters
·
Aug 11

Scynexis Inc Expected to Post a Loss of 51 Cents a Share - Earnings Preview

Reuters
·
Aug 08

NASDAQ Trade Halt Volatility Trading Pause at 11:47 Am

Reuters
·
Jul 31

Scynexis Initiates Phase 1 Study of Scy-770, a Novel Ampk Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd)

Reuters
·
Jul 06

Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)

TIPRANKS
·
Jul 02

Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease

MT Newswires Live
·
Jun 30

Scynexis - Topline Phase 1 Data Expected in Q3 2026

THOMSON REUTERS
·
Jun 30

Scynexis - Phase 2 Study in Adpkd Expected to Begin in Q4 2026

THOMSON REUTERS
·
Jun 30

Scynexis Initiates Phase 1 Study of Scy-770, a Novel Ampk Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd)

THOMSON REUTERS
·
Jun 30

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

GlobeNewswire
·
Jun 30